Table 3.

Sequence analysis of the clonal TCR-β rearrangements obtained from various T-cell lymphomas

Diagnosis Case 3′Vβ N-D-N 5′Jβ VβDβ Jβ
CTCL, skin  12  TGTGCCAGTAGT  TCGGC AGCAATCAGCCCCAGCATTTTGG  V7.2  Dx  J1.5  
CTCL, skin 13  TGTGCCAGT  CAATAAAGGGAGGGTCTGATCT CTACGAGCAGTACTTCGGCCCC  V19  D2  J2.7  
CTCL, LN  13 TGTGCCAGT  CAATAAAGGGAGGGTCTGATCT  CTACGAGCAGTACTTCGGGCCC V19  D2  J2.7  
CTCL, blood  17  TGTTCCAGCAGC TGGGACAGGGGTAG  CTCCTACGAGCAGTACTTCGGCCCC  V5.4  D1 J2.7  
CTCL, blood  17  TGTGCCAGCAGC  TGGGACAGGGGTAG CTCCTACGAGCAGTACTTCGGGCCC  V5.4  D1  J2.7  
PTCL  24 TGTGCCAGCAGCTT  CGGACAGGG  TGGAAACACCATATATTTTGGA  V7.9 D1  J1.3  
PTCL  25  TCTGCAGCGTTGAAGA  CAGGGGTT TCCTACAATGAGCAGTTCTTCGGGCCA  V29.1  D1  J2.1  
PTCL 27  TGTGCCAGCAGCTTAG  TCGGGACAGGAG CCTACAATGAGCAGTTCTTCGGGCCA  V7.2  D1  J2.1  
PTCL  29 TATGCCAGTAGTAT  TGTGAATTC  GAACACTGAAGCTTTCTTTGGA  V19 Dx  J1.1  
PTCL  31  TGTGCCAGTAGTATA ATAGTGGGGGGCAGTGGCG  CTGAAGCTTTCTTTGGA  V19  D1  J1.1 
PTCL  32  TGTGCCAGCAGTTTAT  CGTGGGGTAGCGGTG GCACAGATACGCAGTATTTTGGCCCA  V28  D2  J2.3  
PTCL  32 TGTGCCAGTA  TGAATAGGACAGAG  AATCGAATCAGCCCCATTTTGG  V29.1 D1  J1.5  
T-LBL  41  TGTACTTCTGTGCCAGC  TCCACGTGGGGG CAGCCCCAGCATTTTGG  V27.1  D1  J1.5  
T-LBL  42 TCTGCAGTGCTA  TCTGGGCCGG  CTATAATTCACCCCTCCACTTTGGG  V20.1 Dx  J1.6  
T-LBL  43  TGCAGTGCT  CAGCCTTCGAG GGCTACACCTTCGGTTCGG  V19  D2  J1.2  
T-LBL  45 TCTGCAGCGTT  CCGGGACAGGGTGCACCTACGAG  CAGTACTTCGGGCCA V29.1  D1  J2.5  
ALC-T  50  TGTGCCAGCAGC CTCAGGGGTAAC  AATTCACCCCTCCACTTTGGG  V11.1  D1  J1.6 
ALC-T  52  TGTGCCAGCAGCTTA  AACAGGGGC AATTCACCCCTCCACTTTGGG  V7.2  D1  J1.6  
ALC-T  53 TGTGCCAGTAGC  AAAGGG  AATTCACCCCTCCACTTTGGG  V19  Dx J1.6  
ALC-T  55  TGTGCCAGTAGTATAG  CACGCGGACCCTA TAGCAATCAGCCCCAGCATTTTGG  V19  D2  J1.5  
ALC-T  58 TGTGCCAGCAG  TTTTGGGGGGGCGA  ATGAGCAGTTCTTCGGGCCA  V7.2 D1  J2.1  
ALC-T  58  TGTGCCAGTAG GACACCCTCTGAGGGGGGCGCGG  GCAATCAGCCCCAGCATTTTGG  V19  D1 J1.5  
ITCL  59  TGTGCCAGCAGTTAC  GGACAG AATTCACCCCTCCACTTTGGG  V6.3  Dx  J1.6  
ITCL  60 TGTGCCAGCAGTTACT  GTGGGCCGACG  GAGACCCAGTACTTCGGGCCA  V9 D1  J2.5  
ITCL  61  TGTGCCAGCAGCTTGG TTGACAGGGGGCAGC  ATGGCTACACCTTCGGTTCGGG  V6.5  D1  J1.2 
Cell line MOLT4   TCTGCAGTGCTAG  AGAGTCGACTAGCGATCCAAAA AATGAGCAGTTCTTCGGGCCA  V20.1  D2  J2.1  
Cell line HUT 102   TCTGCAGCGT  AGGCAGGAGGCGGTTGGC  GGCTACACCTTCGGTTCGG V30  D2  J1.2  
Cell line DHL-1   TGTGCCAGTAGTA CAGTAGGGGA  ACAGATACGCAGTATTTTGGCCCA  V27  D1 J2.3 
Diagnosis Case 3′Vβ N-D-N 5′Jβ VβDβ Jβ
CTCL, skin  12  TGTGCCAGTAGT  TCGGC AGCAATCAGCCCCAGCATTTTGG  V7.2  Dx  J1.5  
CTCL, skin 13  TGTGCCAGT  CAATAAAGGGAGGGTCTGATCT CTACGAGCAGTACTTCGGCCCC  V19  D2  J2.7  
CTCL, LN  13 TGTGCCAGT  CAATAAAGGGAGGGTCTGATCT  CTACGAGCAGTACTTCGGGCCC V19  D2  J2.7  
CTCL, blood  17  TGTTCCAGCAGC TGGGACAGGGGTAG  CTCCTACGAGCAGTACTTCGGCCCC  V5.4  D1 J2.7  
CTCL, blood  17  TGTGCCAGCAGC  TGGGACAGGGGTAG CTCCTACGAGCAGTACTTCGGGCCC  V5.4  D1  J2.7  
PTCL  24 TGTGCCAGCAGCTT  CGGACAGGG  TGGAAACACCATATATTTTGGA  V7.9 D1  J1.3  
PTCL  25  TCTGCAGCGTTGAAGA  CAGGGGTT TCCTACAATGAGCAGTTCTTCGGGCCA  V29.1  D1  J2.1  
PTCL 27  TGTGCCAGCAGCTTAG  TCGGGACAGGAG CCTACAATGAGCAGTTCTTCGGGCCA  V7.2  D1  J2.1  
PTCL  29 TATGCCAGTAGTAT  TGTGAATTC  GAACACTGAAGCTTTCTTTGGA  V19 Dx  J1.1  
PTCL  31  TGTGCCAGTAGTATA ATAGTGGGGGGCAGTGGCG  CTGAAGCTTTCTTTGGA  V19  D1  J1.1 
PTCL  32  TGTGCCAGCAGTTTAT  CGTGGGGTAGCGGTG GCACAGATACGCAGTATTTTGGCCCA  V28  D2  J2.3  
PTCL  32 TGTGCCAGTA  TGAATAGGACAGAG  AATCGAATCAGCCCCATTTTGG  V29.1 D1  J1.5  
T-LBL  41  TGTACTTCTGTGCCAGC  TCCACGTGGGGG CAGCCCCAGCATTTTGG  V27.1  D1  J1.5  
T-LBL  42 TCTGCAGTGCTA  TCTGGGCCGG  CTATAATTCACCCCTCCACTTTGGG  V20.1 Dx  J1.6  
T-LBL  43  TGCAGTGCT  CAGCCTTCGAG GGCTACACCTTCGGTTCGG  V19  D2  J1.2  
T-LBL  45 TCTGCAGCGTT  CCGGGACAGGGTGCACCTACGAG  CAGTACTTCGGGCCA V29.1  D1  J2.5  
ALC-T  50  TGTGCCAGCAGC CTCAGGGGTAAC  AATTCACCCCTCCACTTTGGG  V11.1  D1  J1.6 
ALC-T  52  TGTGCCAGCAGCTTA  AACAGGGGC AATTCACCCCTCCACTTTGGG  V7.2  D1  J1.6  
ALC-T  53 TGTGCCAGTAGC  AAAGGG  AATTCACCCCTCCACTTTGGG  V19  Dx J1.6  
ALC-T  55  TGTGCCAGTAGTATAG  CACGCGGACCCTA TAGCAATCAGCCCCAGCATTTTGG  V19  D2  J1.5  
ALC-T  58 TGTGCCAGCAG  TTTTGGGGGGGCGA  ATGAGCAGTTCTTCGGGCCA  V7.2 D1  J2.1  
ALC-T  58  TGTGCCAGTAG GACACCCTCTGAGGGGGGCGCGG  GCAATCAGCCCCAGCATTTTGG  V19  D1 J1.5  
ITCL  59  TGTGCCAGCAGTTAC  GGACAG AATTCACCCCTCCACTTTGGG  V6.3  Dx  J1.6  
ITCL  60 TGTGCCAGCAGTTACT  GTGGGCCGACG  GAGACCCAGTACTTCGGGCCA  V9 D1  J2.5  
ITCL  61  TGTGCCAGCAGCTTGG TTGACAGGGGGCAGC  ATGGCTACACCTTCGGTTCGGG  V6.5  D1  J1.2 
Cell line MOLT4   TCTGCAGTGCTAG  AGAGTCGACTAGCGATCCAAAA AATGAGCAGTTCTTCGGGCCA  V20.1  D2  J2.1  
Cell line HUT 102   TCTGCAGCGT  AGGCAGGAGGCGGTTGGC  GGCTACACCTTCGGTTCGG V30  D2  J1.2  
Cell line DHL-1   TGTGCCAGTAGTA CAGTAGGGGA  ACAGATACGCAGTATTTTGGCCCA  V27  D1 J2.3 

Clonal TCR-β PCR products were directly sequenced. The representative clone-specific CDR3 proportion is shown. The corresponding Vβ germline segments are designated to the nomenclature of Rowen et al.11 The D- and J-segments are aligned according to the nomenclature of Toyonage et al12 and Tunnacliffe et al.13 Dx: D-segment not determinable.

View Large